


PHARMACEUTICAL 2021

F-star Therapeutics Inc. Rank 184 of 402







PHARMACEUTICAL 2021

F-star Therapeutics Inc. Rank 184 of 402



The relative strengths and weaknesses of F-star Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of F-star Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 124% points. The greatest weakness of F-star Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 68% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	26,065
Cost of Goods Sold	0
Intangible Assets	33,912
Liabilities, Current	16,977
Liabilities, Non-Current	2,622
Other Assets	2,843
Other Compr. Net Income	557
Other Expenses	2,385
Other Liabilities	1,016
Other Net Income	-849
Other Revenues	11,256
Property and Equipment	789
Research and Development	14,128
Selling, General and Administrative Expense	19,513

Output Variable	Value in 1000 USD
Assets	63,609
Liabilities	20,615
Expenses	36,026
Revenues	11,256
Stockholders Equity	42,994
Net Income	-25,619
Comprehensive Net Income	-25,340
Economic Capital Ratio	115%

